In vitro biotransformation of the new antipsychotic agent, RWJ-46344 in rat hepatic S9 fraction: API-MS/MS/MS identification of metabolites.
The in vitro biotransformation of the antipsychotic agent, RWJ-46344 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-46344 (approximately 37% of the sample) plus 12 metabolites were profiled, quantified, and tentatively identified on the basis of API (ionspray)-MS/MS/MS data. The proposed metabolic pathways for RWJ-46344 are proposed, and the six metabolic pathways are 1, O-dealkylation; 2, piperidinyl oxidation; 3, N-debenzylation; 4, phenyl hydroxylation; 5, dehydration; and 6, reduction. Pathways 1 to 3 formed O-desisopropyl RWJ-46344 (M3, approximately 13% of the sample) and its hydroxy-metabolite (M5, approximately 8%), hydroxypiperidinyl RWJ-46344 (M1, approximately 5%) and a phenylpiperidinyl metabolite (M8, approximately 24%) as major and moderate metabolites. Eight minor metabolites (each < 2%) were formed via a combination of six steps. RWJ-46344 is metabolized substantially by this rat hepatic system.
Wu
W N
WN
Division of Preclinical Development, The R. W. Johnson Pharmacetical Research Institute, Spring House, PA 19477, USA.
McKown
L A
LA
Moyer
M D
MD
Reitz
A B
AB
D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics*; D001711:Biotransformation; D008099:Liver / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods*; D010880:Piperidines / Q000493:pharmacokinetics*; D051381:Rats
C420454:4-(2-((1-methylethoxy)phenyl)-1-piperidinyl)methylbenzoyl-2,6-dimethylpiperidine; D014150:Antipsychotic Agents; D010880:Piperidines